TICKERNERD
Menu
EYPTEYPTHealthcare · Biotechnology

EYPT Stock Forecast: EyePoint, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$4.23
−0.47% on the day

The 13 Wall Street analysts covering EyePoint, Inc. hold a median 12-month price target of $20 — +372.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$354.6M
Ticker Nerd rank
14 / 100
Median analyst target
$20
Analysts covering
13
Revenue$507K−90.5% y/y
Operating income−$97.4M
Net income−$94.5M
Free cash flow−$63.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.4%
1M
−67.6%
YTD
−76.8%
1Y
−68.3%
From 52W high
−77.6%
From 52W low
0.0%
$4
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EYPT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores EyePoint, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
78
Size
59
Momentum
32
Revisions
31
Issuance
25
Value
21
Quality
21
Growth
19
Volatility
15

Accruals (78): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (15): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EYPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EYPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26EYPTHigh $68Median $20Low $4

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
7 Buy6 Hold0 Sell
Low $4Median $20High $68

The green dot is the last close — the median target sits +372.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
2 Sept 2026TD CowenDowngradeHold$20 → $4.00
18 Aug 2026Chardan CapitalDowngradeNeutral—
18 Aug 2026Chardan CapitalDowngradeNeutral$65 → $5.00
18 Aug 2026CitigroupMaintainsBuy$35 → $17
18 Aug 2026CitigroupMaintainsBuy—
18 Aug 2026HC Wainwright & Co.DowngradeNeutral—
18 Aug 2026HC Wainwright & Co.DowngradeNeutral—
18 Aug 2026RBC CapitalDowngradeSector Perform$37 → $5.00
18 Aug 2026RBC CapitalDowngradeSector Perform—
17 Aug 2026Chardan CapitalMaintainsBuy—
17 Aug 2026Chardan CapitalMaintainsBuy$65
17 Aug 2026JefferiesMaintainsBuy—
17 Aug 2026JefferiesMaintainsBuy$30 → $8.00
17 Aug 2026JP MorganDowngradeNeutral—
17 Aug 2026JP MorganDowngradeNeutral—
7 Aug 2026Chardan CapitalMaintainsBuy—
7 Aug 2026Chardan CapitalMaintainsBuy$65
6 Aug 2026Cantor FitzgeraldMaintainsOverweight—
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$47 → $55
6 Aug 2026HC Wainwright & Co.MaintainsBuy$30 → $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EYPT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EYPT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, EyePoint, Inc. returned −68.3% against +17.5% for the S&P 500, dividends included.

EYPT vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Oct 25Jan 26Apr 26Jul 26EYPTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EYPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
9
Fundamentals

EyePoint, Inc. (EYPT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 83% of US stocks

Price / sales
127.2×

Cheaper than 4% of US stocks

Price / book
10.7×

Cheaper than 9% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
161.7%

Higher than 95% of US stocks

Earnings growth (YoY)
−90.5%

Higher than 3% of US stocks

Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
−450.7%

Higher than 8% of US stocks

Net margin
93.4%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−148.7%

Higher than 9% of US stocks

Return on assets
−74.9%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

EyePoint, Inc. (EYPT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • EyePoint, Inc. has a market value of $354.6M and an enterprise value of $374.0M.

  • Revenue in the twelve months to 30 June 2026: $2.8M. The latest quarter grew 161.7% year on year.

  • Net income over the same four quarters: −$306.6M, a −10994.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.74.

  • Free cash flow in the twelve months to 30 June 2026: −$271.3M.

  • Shares outstanding: 85.0M.

  • Trailing P/E: −1.3×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • EyePoint, Inc. employs 214 people — $13K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

EYPT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EYPTEyePoint, Inc.$354.6M
14
SIONSionna Therapeutics, Inc.$350.3M
26
DMACDiaMedica Therapeutics, Inc.$348.9M
47
IPSCCentury Therapeutics, Inc.$348.5M
39
XFORX4 Pharmaceuticals, Inc.$347.0M
62
OCGNOcugen, Inc.$345.3M
22
OBIOOrchestra Biomed Holdings, Inc.$358.1M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own EyePoint, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EYPT news & analysis

EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

GlobeNewsWire · 10 Sept 2026negative

Kessler Topaz Meltzer & Check, LLP announced it is investigating potential violations of federal securities laws by EyePoint, Inc. The law firm is reaching out to investors who purchased EyePoint securities and experienced significant financial losses.

Why it matters — A securities litigation investigation signals potential legal and regulatory concerns for EyePoint that could carry financial and reputational implications for the company and its shareholders.

EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

EyePoint, Inc. presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published on Seeking Alpha. The presentation covered the company's remarks at the conference.

Why it matters — A Eyepoint watcher would care because it offers insight into how the company communicates its strategy and updates to investors at a notable industry conference.

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

PRNewsWire · 6 Sept 2026negative

Kessler Topaz Meltzer & Check, LLP announced it is investigating potential violations of federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased EyePoint securities and experienced significant financial losses.

Why it matters — EYPT watchers would care because a securities litigation firm is probing possible securities law violations tied to investor losses in the company.

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

GlobeNewsWire · 2 Sept 2026neutral

EyePoint, Inc. announced it will participate in several upcoming investor conferences and a scientific meeting. The company made the announcement on September 2, 2026, from its headquarters in Watertown, Massachusetts.

Why it matters — EYPT watchers would care because these conference appearances provide opportunities for the company to present its therapeutic pipeline to investors and the scientific community, offering potential visibility into its progress.

EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Business Wire · 2 Sept 2026negative

Kirby McInerney LLP announced an investigation into EyePoint Pharmaceuticals over possible federal securities law violations by the company and/or its senior management. The investigation relates to topline results EyePoint released on August 14, 2026 from its Phase 3 LUGANO wet AMD trial for DURAVYU.

Why it matters — EYPT watchers would care because the legal investigation could affect the company's standing and reflects investor concerns following the release of the DURAVYU trial results.

FAQ

Frequently asked questions about EYPT stock

What is the EYPT stock price forecast for 2026-2027?

The 13 Wall Street analysts covering EyePoint, Inc. have a median 12-month price target of $20, with estimates ranging from $4 to $68. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EYPT stock a buy right now?

Of the 13 analysts covering EyePoint, Inc., 7 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks EyePoint, Inc. 14 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EYPT?

As at 12 Sept 2026, EyePoint, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (78 of 100).

Will EYPT stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +372.8% from the last close, and Ticker Nerd's factor model ranks EyePoint, Inc. 14 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EYPT stock forecast for 2030?

No analyst covering EyePoint, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EYPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $68 over the next 12 months.

How has EYPT stock performed over the past year?

EyePoint, Inc. returned -68.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does EyePoint, Inc. do?

EyePoint, Inc. Common Stock represents equity in EyePoint, Inc., a biopharmaceutical company focused on developing and commercializing therapies for serious retinal diseases.

What is the latest news on EYPT?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP". Kessler Topaz Meltzer & Check, LLP announced it is investigating potential violations of federal securities laws by EyePoint, Inc. The law firm is reaching out to investors who purchased EyePoint securities and experienced significant financial losses.

Company

About EyePoint, Inc.

EyePoint, Inc. Common Stock represents equity in EyePoint, Inc., a biopharmaceutical company focused on developing and commercializing therapies for serious retinal diseases. The company’s current portfolio centers on ophthalmology products and sustained-release drug delivery technologies designed to treat eye disorders and improve the management of retinal conditions. Its marketed and development-stage programs address areas such as retinal vascular disease, diabetic macular edema, and other eye diseases, using proprietary platforms that support localized, long-acting treatment delivery. EyePoint, Inc. serves the specialized eye-care market, working with healthcare providers and the broader ophthalmic industry through products and pipeline assets that target chronic retinal conditions. Headquartered in Watertown, Massachusetts, the company is positioned within the life sciences sector as a developer of therapies and drug-delivery systems for ophthalmic use.

CEO Dr. Jay S. Duker M.D. · 214 employees · United States · https://eyepoint.bio